Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and 177Lu-Dotatate in Neuroendocrine Tumors
NCT07012330Phase 2Terminated
- Sponsor
- Erasmus MC
- Start
- Mar 2007
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in gastroenteropancreatic neuroendocrine tumor (GEP-NET), bronchopulmonary neuroendocrine tumor (BP-NET), sponsored by Erasmus MC. Started Mar 2007; status: terminated.
02
Drugs
capecitabine
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)bronchopulmonary neuroendocrine tumor (BP-NET)
Beyond the preview
Go deeper on NCT07012330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012330.